Migraine in Medical Technology

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

MOUNTAIN VIEW, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has initiated a Phase 2b clinical trial with AZ-104 (Staccato loxapine) in patients with migraine headaches. AZ-104 is a lower-dose version of AZ-004 (Staccato loxap...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

ESSEX, United Kingdom, Oct. 24 /PRNewswire-FirstCall/ -- Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of mi...

Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008

Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disord...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

Company's End-of-Phase II Meeting with FDA Set for Sept. 29 LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to mee...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and Alan J. Tuchman, M.D. LA JOLLA, Calif., June 25 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq:...

ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment

Top-line Data Show Significant Improvements With ROX-828 In Migraine Pain And Related Symptoms For Up to 48 Hours Vs. Placebo MENLO PARK, Calif., April 28 /PRNewswire/ -- ROXRO PHARMA, Inc. today announced positive top-line data from a clinical study of the company's novel investigatio...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

Initial Analysis Shows Statistically Significant Pain Relief with the 2.5 and 5 mg Doses Compared to Placebo MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today positive top-line results from its 168 patient Ph...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

Initial Results Expected to be Reported in Q1 2008 PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has completed its target patient enrollment in its Phase 2a proof-of-concept clinical trial with AZ-104 (Stac...

Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in First Half of 2008 - LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose cli...

A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females

REHOVOT, Israel, Nov. 6 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today that the primary end point and safety evaluation in the Phase II, Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in Migraine patients was successfully completed. This event marks a major mil...

Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache

- Company Plans to Move Compound Forward into Phase III - - Conference Call Scheduled for Today at 9:00 A.M., Eastern Time - LA JOLLA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that tezampanel met the primary endpoint in ...

TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache

- Top Line Results Expected to Be Reported in 4Q 2007 - LA JOLLA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that it has completed enrollment in its Phase IIb clinical trial of tezampanel for the treatment of acute migraine ...

Swedish in Seattle to Study Connections Between Preeclampsia and Migraine

- $2.9 million research grant awarded by NIH; Findings could benefit pregnant women worldwide SEATTLE, Sept. 29 /PRNewswire-USNewswire/ -- The National Institute of Child Health and Human Development division of the National Institutes of Health (NIH) has awarded Michelle A. Williams, Sc.D.,...

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine. MAP0004 is orally inhaled and self-administered at home using MAP Pharm...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

Clinical studies show Treximet provided significantly more patients migraine pain relief compared to sumatriptan 85 mg LONDON, April 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK ) and POZEN Inc. (Nasdaq: POZN ) announced today that the FDA has approved Trexi...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks

Study Results Show Individuals Reported Consistent Pain-Free Results From Attack to Attack BOSTON, May 02, 2007 /PRNewswire/ -- Patients who suffer from migraines frequently cite inconsistent effectiveness as a reason for their dissatisfaction with their medicine. New data from more than 1,100 pat...

Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms

New data show efficacy across the range of migraine symptoms BOSTON, May 02, 2007 /PRNewswire/ -- While many migraine sufferers experience traditional symptoms such as nausea or sensitivity to light and sound, migraine attacks can also involve symptoms like neck pain or sinus pain that are not tra...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundreds of migraine patients and physicians commissioned by the National Headache Foundation and conducted by Harris Interactive shows that 20 percent of migraine patients are currently...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from a Phase II study presented for the first time at the American Headache Society (AHS) annual meeting showed that MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved migraine ...

Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statis...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., a privately held specialty pharmaceutical company, today announced positive results from an initial Phase I study of NP101 SmartRelief, a novel treatment for acute migraine being developed by NuPathe. NP101 combines NuPathe's SmartRel...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network) -- Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), has presented results from a Phase III randomized, double-blind, placebo-controlled clinical trial evaluating Frova (frovatr...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

...66 and U01 HL65962 and American Heart Association grant 0940116N; by the German Federal Ministry of Education and Research (01GI9909/3), by the German migraine & Headache Society (DMKG), and by unrestricted grants of equal share from Astra Zeneca, Berlin Chemie, Boots Healthcare, Glaxo-Smith-Kline, McNeil...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

...petic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OP...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...apine). Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-004. In January 2009, Ale...ng. Both product candidates are being developed for the acute treatment of migraine headache. AZ-002 ( Staccato alprazolam) has completed Phase 1 testing and...

Study Confirms: Your Hidden Food Allergies Are Making You Fat

...he benefit of The ALCAT Test to help chronic symptoms such as obesity, IBS, migraine and arthritis. DEERFIELD BEACH, Fla., April 6 /PRNewswire/ -- Medical ...t. Food sensitivities often provoke delayed and chronic symptoms, like IBS, migraine and arthritis, that are not as obvious as the dramatic and immediate onset ...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...petic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OP...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

...petic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OP...

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

...petic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OP...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

...The Company has completed its end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), which is intended for the acute treatment of migraine headache, and it has advanced AZ-104 (Staccato loxapine) to Phase 2 testing. Product candidates that have completed Phase 1 testing are AZ-003 (Stacc...

Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures

...roviding solutions that improve neurological health. The company currently markets products for Alzheimer's disease, epilepsy and acute and preventive migraine treatment. In conjunction with internal and external research partners, Ortho-McNeil Neurologics continues to explore new opportunities to develop sol...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

...renic or bipolar disorder patients, has completed one Phase 3 clinical trial and the second Phase 3 clinical trial ongoing. For the acute treatment of migraine headaches, AZ-001 (Staccato prochlorperazine) has completed Phase 2 testing and AZ-104 (Staccato loxapine) is in Phase 2 testing. Product candidates i...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...ping AZ-001 to treat patients suffering from acute migraine headaches. Alexza requested an end of Phase 2 meet...ping AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-00... was allowed to conduct the first patient study in migraine patients, the Phase 2a proof-of-concept trial note...

FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months

... as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome. TOPAMAX(R) is indicated in adults for the prophylaxis of migraine headache. Important Safety Information: Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increa...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...o prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product can...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

...revious study of healthy volunteers. "Asthma and migraine have a high incidence of co-morbidity, so it was i... has a long history of use as a safe and effective migraine treatment. Many headache specialists consider DHE ...ion to be the standard of care in treating chronic migraine and debilitating migraines that last more than 72 ...

Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting

... device would help an estimated 39 percent of migraine sufferers. The device, about the size and wei...he ticket to help relieve the pain of chronic migraine sufferers. Occipital nerve stimulation, in which a...m, has been shown to help 40 percent of near-daily migraine sufferers who don't have success with standar...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

...Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of ... Reduces Headache Pain in Patients Having an Acute migraine Attack", is scheduled for Friday, June 27, 2008 at...104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...o prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product can...